
    
      Aim: To determine the importance of the GIP system in patients with acromegaly who has
      paradoxical growth hormone secretion during an oral glucose tolerance test (OGTT) using a GIP
      antagonist (GIP-A).

      Thirty participants (age 18-75 years) with normal kidney and liver parameters and hemoglobin
      levels will be included in a placebo-controlled cross-over study. The study consists of two
      study days with concomitant infusions of A) GIP-A or B) saline (placebo).
    
  